.webp)
The Future of PV in the Era of Advancing AI Regulations: What QPPVs Must Know
WEBINAR OVERVIEW:
This live webinar, hosted by PrimeVigilance, will explore the rapidly expanding regulatory complexity that Qualified Persons for Pharmacovigilance (QPPVs) and Safety Leaders must navigate as artificial intelligence becomes increasingly embedded in pharmacovigilance (PV) operations. Attendees will gain practical insights into current AI adoption across PV workflows, emerging regulatory expectations from global health authorities, and the industry and legislative developments that are reshaping governance of AI-enabled systems in GxP environments. The session will also examine the changing responsibilities of QPPVs, highlighting why accountability remains with human oversight, how AI decision-making parameters should be defined and documented, and the latest regulatory lessons learned from inspections, enforcement actions, and evolving compliance requirements.
-
Understanding of regulatory expectations for AI-enabled pharmacovigilance systems in 2026 and beyond
-
Practical approaches to establish AI governance boundaries that maintain QPPV accountability
-
Implementable strategies to align PV quality systems with the EU AI Act and pharma-specific regulations
-
Insight into how Safety Leaders can proactively lead the transformation of pharmacovigilance operations
-
Strategies to maintain inspection-ready AI governance through robust documentation, oversight and QPPV accountability
- QPPVs and Deputy QPPVs
-
Heads/Directors of Pharmacovigilance and Drug Safety
-
PV Quality and Compliance Leaders
- PV Operations Leaders
- Quality Assurance / GxP Quality Professionals
- Computerised Systems Quality / CSV Professionals
- AI Governance and Compliance Professionals
- Regulatory Affairs Professionals
- Safety Technology / PV Systems Leaders
Nikodem Latocha
Associate Director Quality - Computerized Systems Quality
PrimeVigilance

With over a decade of leadership experience in Computerized Systems Validation and quality assurance, I have become passionate about the ways AI can impact not only the pharmaceutical and biotech industries but also the most vulnerable individuals - patients. Exploring ways to embed the complex, dynamic nature of AI laws and regulatory guidelines into company-specific processes and procedures.
Jana D'Alascio
Senior Director, QPPV
PrimeVigilance

Doctor of veterinary medicine with 2 decades of experience in pharmacovigilance and clinical safety. Profound experience as Qualified Person responsible for Pharmacovigilance in the EU/UK and Graduated Plan Officer in Germany. Continuously exposed to audits and inspections, in particular by the federal and regional Competent Authorities in Germany. Expertise in numerous indications and various stages of development from First-In-Men until Post-Marketing in service provider companies and pharmaceutical industry.
